On Apr. 28, 2020, Chimerix announced it had received clearance from the FDA for a rolling submission of its New Drug Application for the approval of brincidofovir (BCV) as a medical countermeasure for smallpox. The Company intended to begin a rolling NDA submission for BCV in May 2020 with completion targeted for mid-2020.